New dimensions in vascular engineering: opportunities for cancer biology
- PMID: 20367255
- PMCID: PMC2947931
- DOI: 10.1089/ten.TEA.2010.0183
New dimensions in vascular engineering: opportunities for cancer biology
Abstract
Angiogenesis is a fundamental prerequisite for tissue growth and thus an attractive target for cancer therapeutics. However, current efforts to halt tumor growth using antiangiogenic agents have been met with limited success. A reason for this may be that studies aimed at understanding tissue and organ formation have to this point utilized two-dimensional cell culture techniques, which fail to faithfully mimic the pathological architecture of disease in an in vivo context. In this issue of Tissue Engineering, the work of Fischbach-Teschl's group manipulate such variables as oxygen concentration, culture three-dimensionality, and cell-extracellular matrix interactions to more closely approximate the biophysical and biochemical microenvironment of tumor angiogenesis. In this article, we discuss how novel tissue engineering platforms provide a framework for the study of tumorigenesis under pathophysiologically relevant in vitro culture conditions.
Similar articles
-
Tissue-engineered three-dimensional tumor models to study tumor angiogenesis.Tissue Eng Part A. 2010 Jul;16(7):2147-52. doi: 10.1089/ten.tea.2009.0668. Tissue Eng Part A. 2010. PMID: 20214471 Free PMC article. Review.
-
Translating tissue engineering technology platforms into cancer research.J Cell Mol Med. 2009 Aug;13(8A):1417-27. doi: 10.1111/j.1582-4934.2009.00853.x. Epub 2009 Jul 20. J Cell Mol Med. 2009. PMID: 19627398 Free PMC article. Review.
-
3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways.Biomaterials. 2015 Jul;55:110-8. doi: 10.1016/j.biomaterials.2015.03.035. Epub 2015 Apr 13. Biomaterials. 2015. PMID: 25934456 Free PMC article.
-
Studying the influence of angiogenesis in in vitro cancer model systems.Adv Drug Deliv Rev. 2016 Feb 1;97:250-9. doi: 10.1016/j.addr.2015.11.004. Epub 2015 Nov 10. Adv Drug Deliv Rev. 2016. PMID: 26571106 Review.
-
Advances in on-chip vascularization.Regen Med. 2017 Apr;12(3):285-302. doi: 10.2217/rme-2016-0152. Epub 2017 Mar 20. Regen Med. 2017. PMID: 28318376 Free PMC article. Review.
Cited by
-
Recapitulation of the embryonic cardiovascular progenitor cell niche.Biomaterials. 2011 Apr;32(11):2748-56. doi: 10.1016/j.biomaterials.2010.12.046. Epub 2011 Jan 22. Biomaterials. 2011. PMID: 21257198 Free PMC article.
-
The effect of delivering the chemokine SDF-1α in a matrix-bound manner on myogenesis.Biomaterials. 2014 May;35(15):4525-4535. doi: 10.1016/j.biomaterials.2014.02.008. Epub 2014 Mar 5. Biomaterials. 2014. PMID: 24612919 Free PMC article.
References
-
- Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182. - PubMed
-
- Hanahan D. Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. J Cell. 1996;86:353. - PubMed
-
- Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;I:27. - PubMed
-
- Bergers G. Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401. - PubMed
Publication types
MeSH terms
Grants and funding
- R01HL075234/HL/NHLBI NIH HHS/United States
- U01 HL066952/HL/NHLBI NIH HHS/United States
- R01 HL058707/HL/NHLBI NIH HHS/United States
- P50 HL084936/HL/NHLBI NIH HHS/United States
- R01HL097797/HL/NHLBI NIH HHS/United States
- RC1 AI080309/AI/NIAID NIH HHS/United States
- R01 HL097797/HL/NHLBI NIH HHS/United States
- R01 HL075234/HL/NHLBI NIH HHS/United States
- R21 HL083222/HL/NHLBI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- P01 HL067839/HL/NHLBI NIH HHS/United States
- P01 HL059312/HL/NHLBI NIH HHS/United States
- R01 HL061849/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous